- Investing Ideas
- Australian Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Australian Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Results
3
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
3 companies
Mesoblast
Market Cap: AU$3.1b
Engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland.
MSB
AU$2.35
7D
-2.1%
1Y
-4.5%
Aroa Biosurgery
Market Cap: AU$198.9m
Develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally.
ARX
AU$0.56
7D
-2.6%
1Y
-7.4%
Telix Pharmaceuticals
Market Cap: AU$5.5b
A commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals.
TLX
AU$16.16
7D
-3.6%
1Y
-14.6%